Document is current
Any future updates will be listed below
-
Authors
Zhang, Jian
McAndrew, Nicholas P.
Wang, Xiaojia
Du, Yiqun
DiCarlo, Brian
Wang, Mei
Chen, Kan
Yu, Wenlei
Hu, Xichun
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04509596 at ClinicalTrials.govDocuments that mention this clinical trial
Preclinical and clinical activity of DZD1516, a full blood–brain barrier-penetrant, highly selective HER2 inhibitor
https://doi.org/10.1186/s13058-023-01679-4
-
Funding
Funding for this research was provided by:
Dizal pharmaceutical
- License Information
-
More Information
Article History
Received: 5 January 2023
Accepted: 25 June 2023
First Online: 6 July 2023
Declarations
:
: The study was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines and with the approval of local institutional review boards/independent ethics committees at participating sites. All patients provided written informed consent to participate.
: Not applicable.
: Nicholas P. McAndrew received research funding to his institution from Novartis, Daiichi Sankyo, Seattle Genetics, and Dizal, advisory board honorarium from Novartis, Daiichi Sankyo, Biotheranostics, and Genomic Health, consulting honorarium from Novartis, Daiichi Sankyo, and GoodRx, travel accommodation from TRIO, Daiichi Sankyo, and Roche, as well as speaking honorarium from Novartis. Mei Wang, Kan Chen, and Wenlei Yu are full-time employees of Dizal Pharmaceutical. The other authors reported no disclosures.
